Among the eight patients who developed metachronous dMMR/MSI-H cancers, 75% carried a pathogenic variant in MSH2, suggesting that this subgroup of LS patients has a higher probability of developing metachronous cancer compared with those with other gene mutations. The gene discussed is MSH2; the disease is cancer.